Treats generalized tonic-clonic status epilepticus and prevention and treatment of…. ANDA 77989, held by Hikma. Fosphenytoin Sodium.
As of Nov 16, 2026, ANDA 77989 (Fosphenytoin Sodium), held by Hikma, was first approved by FDA on Aug 6, 2007, with 7 approved supplements and 0 published complete response letters.
Fosphenytoin sodium injection is indicated for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. Fosphenytoin sodium injection can also be substituted, short-term, for oral phenytoin. Fosphenytoin sodium injection should be used only when oral phenytoin administration is not possible.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 6, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fosphenytoin SodiumEQ 50MG PHENYTOIN NA/ML · injectable;injection | Fosphenytoin Sodium | Rx |
| Jan 25, 2017 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 25, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 2, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 2, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 2, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 2, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 25, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 6, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters